EMQN (European Molecular Genetics Quality Network)

emqn.org

The EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

news image

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More

MEDICAL

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

news image

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

news image

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More

MEDICAL

GE HEALTHCARE INTRODUCES WIRELESS PATIENT MONITORING SOLUTION TO HELP CLINICIANS DETECT EARLY PATIENT DETERIORATION

GE | June 20, 2022

news image

With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4. Portrait Mobile includes ...

Read More
news image

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More
news image

MEDICAL

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More
news image

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More
news image

MEDICAL

GE HEALTHCARE INTRODUCES WIRELESS PATIENT MONITORING SOLUTION TO HELP CLINICIANS DETECT EARLY PATIENT DETERIORATION

GE | June 20, 2022

With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4. Portrait Mobile includes ...

Read More